Investigating genetic factors in immune-related side effects from cancer immunotherapy
IL-6 and IL-6R genetic polymorphisms in immune-related adverse events caused by cancer immunotherapy
This study is looking at how certain genes might affect the chances of experiencing side effects from cancer immunotherapy, especially for those using immunocheckpoint inhibitors, and it aims to help identify patients who may be at higher risk so that we can find ways to reduce these side effects while still keeping the treatment effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10997213 on NIH RePORTER |
What this research studies
This research focuses on understanding how genetic variations in the IL-6 and IL-6R genes may influence the occurrence of immune-related adverse events (irAEs) in patients receiving cancer immunotherapy, particularly immunocheckpoint inhibitors. By analyzing patient samples, the study aims to identify those at higher risk for these side effects and explore mechanisms that drive these reactions. The goal is to develop strategies to minimize these adverse effects while maintaining the effectiveness of cancer treatments. Patients may be asked to provide genetic samples and health information to support this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing immunotherapy who may be at risk for immune-related adverse events.
Not a fit: Patients who are not receiving immunotherapy or those with no genetic predisposition to immune-related adverse events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment plans that reduce the risk of severe side effects from cancer immunotherapy.
How similar studies have performed: Previous research has shown that genetic factors can influence the occurrence of adverse events in other treatments, suggesting that this approach may yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Rincon, Mercedes — University of Colorado Denver
- Study coordinator: Rincon, Mercedes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.